e-Drug3D

1854

CALICHEAMICIN

INN
CALICHEAMICIN
INOTUZUMAB OZOGAMICIN
GEMTUZUMAB OZOGAMICIN

cas 108212-76-6

CLASS

ANTINEOPLASTIC
TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
CD33- OR CD22-DIRECTED ANTIBODY-DRUG CONJUGATE (ADC)
RELEASE OF N-ACETYL-GAMMA-CALICHEAMICIN THAT CAUSES DOUBLE-STRANDED DNA BREAKS

ROUTE (list)

INJECTION

ATC code

L01FB01

PK parameters

PPB 97 PERCENT

Target

TARGET DNA

DrugCentral

B-cell receptor CD22 UNIPROT P20273 CD22_HUMAN

Download SDF file

arbamic acid, [(1R,4Z,8S,13E)-8-[[2-O-[4-(acetylethylamino)-2,4-dideoxy-3-O-methyl-alpha-L-threo-pentopyranosyl]-4,6-dideoxy-4-[[[2,6-dideoxy-4-S-[4-[(6-deoxy-3-O-methyl-alpha-L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl]-4-thio-beta-D-ribo-hexopyranosyl]oxy]amino]-beta-D-glucopyranosyl]oxy]-1-hydroxy-13-[2-(methyltrithio)ethylidene]-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl]-, methyl ester

Formula:
C57H76IN3O22S4

Calculated chemical properties:

MW 1409.38
NB_atoms 87
XLogP 2.42
PSA 314.847
NB_HD 7
NB_HA 25
fsp3 0.65
Lipinski(0=no;1=yes) 0

FDA
NDA 021174 (label) INN (GEMTUZUMAB OZOGAMICIN) MYLOTARG (WYETH PHARMS INC) APPROVAL= AP YEAR= 2000 NEWMOLECULARENTITY DISCONTINUED OBSOLETE
NDA 761040 (label) INN (INOTUZUMAB OZOGAMICIN) BESPONSA (WYETH PHARMS INC) APPROVAL= AP YEAR= 2017 NEWMOLECULARENTITY
NDA 761060 (label) INN (GEMTUZUMAB OZOGAMICIN) MYLOTARG (WYETH PHARMS INC) APPROVAL= AP YEAR= 2017